Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single‐centre experience.
- Resource Type
- Article
- Authors
- Qi, Peijing; Wang, Linya; Li, Hongqiao; Wu, Ying; Fan, Jia; Huang, Pengli; Hou, Bei; Liu, Mengjia; Yang, Jie; Liu, Huiqing; Yu, Jiaole; Lin, Wei; Zhang, Yuanyuan; Zhang, Ruidong; Lu, Yu; Huang, Qian; Liu, Yan; Zheng, Huyong
- Source
- British Journal of Haematology. Dec2023, Vol. 203 Issue 5, p892-895. 4p.
- Subject
- *ACUTE promyelocytic leukemia
*VENETOCLAX
*PEDIATRIC therapy
- Language
- ISSN
- 0007-1048
A study published in the British Journal of Haematology examines the use of venetoclax as a cytoreduction therapy for pediatric acute promyelocytic leukemia (APL). The study included 11 children with APL who were treated with arsenic and all-trans-retinoic acid (ATRA) in combination with either traditional cytoreduction therapy or venetoclax cytoreduction therapy. The patients treated with venetoclax had a higher rate of achieving hematological complete remission (HCR) on Day 28 of induction compared to those treated with traditional cytoreduction. Venetoclax also resulted in a lower incidence of differentiation syndrome (DS) and reduced reliance on platelet and plasma infusion. However, more research is needed to confirm these findings and evaluate the safety and effectiveness of venetoclax in this population. [Extracted from the article]